Asthma pill for kids shows promise, but study halted early
NCT ID NCT03650400
First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study looked at how a new chewable asthma tablet called fevipiprant works in children aged 6 to 12. The goal was to find the right dose and check for side effects. Only 11 children took part, and the study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Minneapolis, Minnesota, 55402, United States
-
Novartis Investigative Site
Columbia, Missouri, 65203, United States
-
Novartis Investigative Site
Tulsa, Oklahoma, 74136, United States
-
Novartis Investigative Site
Boerne, Texas, 78006, United States
-
Novartis Investigative Site
El Paso, Texas, 79903, United States
-
Novartis Investigative Site
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.